Literature DB >> 7999409

Serum levels of tumour necrosis factor-alpha in patients with B-cell chronic lymphocytic leukaemia.

F Adami1, A Guarini, M Pini, F Siviero, R Sancetta, M Massaia, L Trentin, R Foà, G Semenzato.   

Abstract

Serum levels of tumour necrosis factor-alpha (TNF-alpha) have been evaluated in the peripheral blood of 91 patients with B-cell chronic lymphocytic leukaemia (B-CLL), and have been correlated with the clinical stage (according to Rai's staging system) and relevant haematological and immunological data. Increased values were detected, compared to 36 normal age-matched controls (36 pg/ml +/- 5 versus 0.11 pg/ml +/- 0.08; P < 0.05). An increase of TNF-alpha serum levels was observed in all stages including stage 0, with a progressive increase in relation to the stage of the disease. A significant relationship between serum TNF-alpha levels and the number of circulating monocytes (P < 0.002) and an inverse correlation with the level of the haemoglobin (P < 0.001) was established, as defined by the Pearson's correlation test. In contrast, no correlation was observed between TNF-alpha serum levels and the other parameters taken into account, including the white blood cell and platelet counts, the absolute number of peripheral blood (PB) lymphocytes, CD5+ B lymphocytes, CD57+ lymphocytes, serum levels of lactic dehydrogenase, total serum immunoglobulins and the serum levels of IgG, IgA and IgM. These data suggest that, in addition to the B-CLL neoplastic cells, the PB monocytes may be involved in the release of TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999409     DOI: 10.1016/0959-8049(94)90169-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer-indications for anti-TNF-α agents in cancer treatment.

Authors:  M Grimm; M Lazariotou; S Kircher; A Höfelmayr; C T Germer; B H A von Rahden; A M Waaga-Gasser; M Gasser
Journal:  Cell Oncol (Dordr)       Date:  2011-08       Impact factor: 6.730

2.  Cytokine expression in B-CLL in relation to disease progression and in vitro activation.

Authors:  M Aguilar-Santelises; D Gigliotti; L M Osorio; A D Santiago; H Mellstedt; M Jondal
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

3.  Rituximab for the treatment of patients with chronic lymphocytic leukemia.

Authors:  M Gentile; E Vigna; C Mazzone; E Lucia; Ag Recchia; L Morabito; Mg Bisconte; C Gentile; F Morabito
Journal:  Cancer Manag Res       Date:  2010-03-11       Impact factor: 3.989

4.  Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas.

Authors:  A Vacca; D Ribatti; L Ruco; F Giacchetta; B Nico; F Quondamatteo; R Ria; M Iurlaro; F Dammacco
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

5.  Different role of tumor necrosis factor-α polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysis.

Authors:  Kan Zhai; Jie Ding; Yan Zhou
Journal:  Int J Mol Sci       Date:  2014-05-05       Impact factor: 5.923

6.  Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.

Authors:  Claudia Dürr; Bola S Hanna; Angela Schulz; Fabienne Lucas; Manuela Zucknick; Axel Benner; Andrew Clear; Sibylle Ohl; Selcen Öztürk; Thorsten Zenz; Stephan Stilgenbauer; Min Li-Weber; Peter H Krammer; John G Gribben; Peter Lichter; Martina Seiffert
Journal:  Haematologica       Date:  2018-01-11       Impact factor: 9.941

Review 7.  Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.

Authors:  María Florencia Mercogliano; Sofía Bruni; Florencia Mauro; Patricia Virginia Elizalde; Roxana Schillaci
Journal:  Cancers (Basel)       Date:  2021-02-02       Impact factor: 6.639

8.  Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia.

Authors:  I Frydecka; A Kosmaczewska; D Bocko; L Ciszak; D Wolowiec; K Kuliczkowski; I Kochanowska
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

9.  A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Authors:  J A Woyach; T S Lin; M S Lucas; N Heerema; M E Moran; C Cheney; D M Lucas; L Wei; M A Caligiuri; J C Byrd
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

10.  Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia.

Authors:  Helen Marie Parry; Sarah Damery; Christopher Hudson; Matthew J Maurer; James R Cerhan; Annette Pachnio; Jusnara Begum; Susan L Slager; Christopher Fegan; Stephen Man; Christopher Pepper; Tait D Shanafelt; Guy Pratt; Paul A H Moss
Journal:  Am J Hematol       Date:  2016-06-01       Impact factor: 10.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.